CLSA Events

Life Sciences Series: Therapeutic Focus: Bridging the Valley of Death

Large pharmaceutical companies often tap biotech for novel technologies to replenish the product pipeline. Enter the financial crisis of 2009. Restless investors, dormant equity markets, and limited exit opportunities amplified the risk life science innovation faces in the lab.

As the Valley of Death widens, our industry is faced with key questions:

  • Can entrepreneurs continue to streamline their business models while effectively developing novel technologies?
  • Will there be a sufficient number of products moving into late stage development to sustain the industry?
  • What expectations do pharmaceutical companies place on innovation coming from small biotech companies?
  • What will Pharma fund and how will they measure success?

A panel of key industry stakeholders will discuss challenges facing the industry and offer their outlook on the future. They will engage in a thoughtful dialogue with the audience to generate practical and actionable ideas for navigating the Valley of Death.


John Hallinan
Chief Financial Officer, Cytel Inc.


Ted Torphy, PhD
Vice President & Global Head
External Innovation & Business Models
Johnson & Johnson

Richard A. Lindberg, PhD
Senior Director and Head of the
Centers for Therapeutic Innovation – California (CTI-California)
Pfizer Inc.

Manuel López-Figueroa, PhD
Vice President
BayCity Capital

David Nicholson, PhD
Sr. Vice President and Head
Worldwide Licensing and Knowledge Management

What: Therapeutic Focus:
Bridging the Valley of Death
When: Thursday, October 27, 2011
Registration Opens: 3:30pm
Panel Presentation: 4:00pm – 5:30pm
Networking Reception: 5:30pm – 6:30pm
Where: South San Francisco Conference Center
255 South Airport Blvd.
South San Francisco, CA
Parking: Multiple Lot Options
Getting There: Public Transportation Information
Cost: Pre-registration through October 26
$20 BayBio Members
$40 Non-Members
On-site registration on October 27
$40 BayBio Members
$75 Non-Members
Attire: Business attire suggested